The EUROSTARS grant of a EUR 1.8 million fibrosis imaging program is awarded to a multidisciplinary consortium including BiOrion Technologies BV, Zealand Pharma A/S and Akademiska Sjukhuset, PET Centre, University Uppsala. EUROSTARS is a joint program between EUREKA and the European Commission, co-funded from the national budgets of 36 EUROSTARS Participating States and Partner Countries and by the European Union through Horizon 2020. The subsidy is for a three-year period and will allow clinical development of a PDGF beta receptor binding bicyclic peptide conjugated to a PET radionuclide to image hepatic fibrosis.
Herman Steen, CEO of BiOrion, “We are delighted with the recognition and support for our PDGF beta receptor binding bicyclic peptide drug-targeting program by EUROSTARS. This strong and synergistic consortium will enable BiOrion to progress clinical development of our novel targeted therapeutics against fibrosis, not only in liver.”
About BiOrion Technologies BiOrion is a Dutch clinical stage biopharmaceutical drug discovery company founded in 2007, engaged in developing targeted therapeutics and companion imaging diagnostics for fibrotic diseases. These diseases include cardiac fibrosis and hepatic fibrosis, and fibrosis-associated cancers such as colorectal cancer. BiOrion’s platform and drug development engine is based on proprietary PDGF-ß-receptor binding bicyclic peptides that act as targeting vehicles for diagnostic PET radionuclides and (existing) anti-fibrotic therapeutics.
About Zealand Pharma Zealand Pharma A/S was founded in 1997 and is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand Pharma intends to be a leader in specialty medicines focusing on metabolic and gastrointestinal diseases and other specialty disease areas with significant unmet medical needs.
About Akademiska Sjukhuset, PET Centre Akademiska Sjukhuset is a leading University hospital in Sweden with 8000 employees. The PET Centre at the hospital was created in 1991 and performs about 1900 clinical PET investigations per year including around 350 for clinical research, with 25 different PET tracers. PET Centre performs also research in radiochemistry and preclinical PET.
For BiOrion Technologies BV: Herman Steen, PhD CEO BiOrion Technologies BV email@example.com